Company news
An2 Therapeutics, Inc. (NASDAQ:ANTX) news
Every An2 Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of ...
August 31, 2026
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
August 24, 2026
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
August 11, 2026
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
June 4, 2026
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
May 21, 2026
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
May 11, 2026
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
May 7, 2026
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Comple...
March 31, 2026
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
March 17, 2026
AN2 Therapeutics Announces $40 Million Private Placement Financing
March 9, 2026
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
March 3, 2026
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
February 17, 2026
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M...
January 12, 2026
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
November 12, 2025
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
November 10, 2025
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
November 6, 2025
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
August 12, 2025
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
August 12, 2025
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
July 23, 2025
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-C...
June 30, 2025
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
May 29, 2025
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
May 13, 2025
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron C...
May 1, 2025
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
April 30, 2025
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
March 25, 2025
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
March 3, 2025
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
February 24, 2025
AN2 Therapeutics to Participate at Upcoming Investor Conferences
February 20, 2025
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Che...
November 13, 2024
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculos...
October 17, 2024
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
August 16, 2024
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
August 13, 2024
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex ...
August 8, 2024
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
May 14, 2024
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
March 28, 2024
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory ...
February 12, 2024
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
November 9, 2023
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chag...
October 18, 2023
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
September 26, 2023
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium ...
September 13, 2023
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
August 15, 2023
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
August 10, 2023
AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 29, 2023
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 9, 2022
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease
October 6, 2022
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
September 29, 2022
AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 11, 2022
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
June 29, 2022
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 10, 2022